N. Niederle

8.3k total citations · 2 hit papers
161 papers, 4.3k citations indexed

About

N. Niederle is a scholar working on Oncology, Genetics and Hematology. According to data from OpenAlex, N. Niederle has authored 161 papers receiving a total of 4.3k indexed citations (citations by other indexed papers that have themselves been cited), including 66 papers in Oncology, 48 papers in Genetics and 45 papers in Hematology. Recurrent topics in N. Niederle's work include Chronic Lymphocytic Leukemia Research (42 papers), Chronic Myeloid Leukemia Treatments (40 papers) and Lymphoma Diagnosis and Treatment (28 papers). N. Niederle is often cited by papers focused on Chronic Lymphocytic Leukemia Research (42 papers), Chronic Myeloid Leukemia Treatments (40 papers) and Lymphoma Diagnosis and Treatment (28 papers). N. Niederle collaborates with scholars based in Germany, United States and Austria. N. Niederle's co-authors include S. Seeber, O. Kloke, Mathias Rummel, Wolfram Brugger, Manfred Welslau, Ulrich Kaiser, Christina Balser, Eckhart Weidmann, Christoph Losem and Axel Hinke and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Blood.

In The Last Decade

N. Niederle

153 papers receiving 4.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

2013 962 citations Mathias Rummel, N. Niederle et al. The Lancet profile →
Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer

1998 786 citations Philippe Rougier, Eric Van Cutsem et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
N. Niederle Germany	28	2.2k	1.8k	1.3k	727	708	161	4.3k
Roberto Giardini Italy	32	1.2k 0.5×	1.7k 1.0×	671 0.5×	661 0.9×	466 0.7×	84	3.2k
Christiane De Wolf‐Peeters Belgium	36	1.5k 0.7×	2.0k 1.1×	674 0.5×	999 1.4×	498 0.7×	59	4.0k
Dok Hyun Yoon South Korea	35	2.4k 1.1×	2.1k 1.2×	572 0.4×	603 0.8×	785 1.1×	303	4.3k
Anna Marina Liberati Italy	31	1.9k 0.9×	1.3k 0.7×	689 0.5×	1.1k 1.5×	332 0.5×	148	3.8k
Paolo G. Gobbi Italy	29	905 0.4×	1.6k 0.9×	686 0.5×	313 0.4×	497 0.7×	86	2.6k
Theodoros P. Vassilakopoulos Greece	26	1.6k 0.7×	1.6k 0.9×	728 0.5×	540 0.7×	316 0.4×	167	3.1k
Lloyd E. Damon United States	27	932 0.4×	893 0.5×	970 0.7×	781 1.1×	329 0.5×	110	3.8k
Pei Lin United States	40	1.8k 0.8×	2.2k 1.2×	1.9k 1.5×	1.7k 2.3×	300 0.4×	224	5.4k
M Leporrier France	26	606 0.3×	1.5k 0.8×	1.6k 1.2×	403 0.6×	317 0.4×	107	3.5k
Theofanis Economopoulos Greece	36	1.6k 0.7×	691 0.4×	352 0.3×	990 1.4×	651 0.9×	124	4.0k

Countries citing papers authored by N. Niederle

Since Specialization

Citations

This map shows the geographic impact of N. Niederle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by N. Niederle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites N. Niederle more than expected).

Fields of papers citing papers by N. Niederle

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by N. Niederle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by N. Niederle. The network helps show where N. Niederle may publish in the future.

Co-authorship network of co-authors of N. Niederle

This figure shows the co-authorship network connecting the top 25 collaborators of N. Niederle. A scholar is included among the top collaborators of N. Niederle based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with N. Niederle. N. Niederle is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Rummel, Mathias, Ulrich Kaiser, Christina Balser, et al.. (2015). Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial. The Lancet Oncology. 17(1). 57–66. 110 indexed citations

Clemens, Michael, Holger Eidtmann, Ulrike Nitz, et al.. (2010). Trastuzumab Single-Drug Therapy after Failure of Cytotoxic Treatment for Metastatic Breast Cancer. Onkologie. 33(8-9). 425–430. 4 indexed citations

Schmid, Peter, Dagmar Kühnhardt, Philipp Kiewe, et al.. (2008). A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines. Annals of Oncology. 19(5). 871–876. 40 indexed citations

Possinger, K., Walter Schippinger, Philipp Kiewe, et al.. (2005). Phase I trial of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines. Journal of Clinical Oncology. 23(16_suppl). 755–755. 3 indexed citations

Thiele, J., H. M. Kvasnicka, Annette Schmitt‐Graeff, et al.. (2001). Bone Marrow Histopathology Predicting Blast Crisis in Chronic Myeloid Leukemia. Acta Haematologica. 105(4). 244–246. 1 indexed citations

Thiele, Jüergen, Hans Michael Kvasnicka, Annette Schmitt‐Graeff, et al.. (2000). Effects of interferon and hydroxyurea on bone marrow fibrosis in chronic myelogenous leukaemia: a comparative retrospective multicentre histological and clinical study. British Journal of Haematology. 108(1). 64–71. 29 indexed citations

Rougier, Philippe, Eric Van Cutsem, Emilio Bajetta, et al.. (1998). Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. The Lancet. 352(9138). 1407–1412. 786 indexed citations breakdown →

Diehl, Volker, Rieke Fischer, J. Thiele, et al.. (1995). The impact of interferon versus busulfan therapy on the reticulin stain-measured fibrosis in CML ? a comparative morphometric study on sequential trephine biopsies. Annals of Hematology. 70(3). 121–128. 5 indexed citations

Heider, Andrea, et al.. (1995). 5-Fluorouracil cardiotoxicity with left ventricular dysfunction under different dosing regimens. The American Journal of Cardiology. 75(2). 194–195. 18 indexed citations

10.

Niederle, N., et al.. (1993). Long-Term Treatment of Chronic Myelogenous Leukemia with Different Interferons: Results from Three Studies. Leukemia & lymphoma. 9(1-2). 111–119. 24 indexed citations

11.

Mülleneisen, Norbert, et al.. (1993). Hypersensitivity reactions to carboplatin. European Journal of Cancer. 29. S208–S208. 6 indexed citations

12.

Kloke, O., et al.. (1992). Opposite Sensitivity to the Antiproliferative Action of Interferon-α and Granulocyte-Macrophage Colony-Stimulating Factor in Monoblastic U937 Cells. Journal of Interferon Research. 12(5). 369–376. 4 indexed citations

13.

Becher, R., O. Kloke, Dieter May, et al.. (1991). Ifosfamide. Methotrexate and 5-Fluorouracil for Pretreated Advanced Breast Cancer. Oncology. 48(6). 459–463. 2 indexed citations

14.

Nowrousian, Mohammad R., N. Niederle, M. Nagel‐Hiemke, et al.. (1991). Etoposide, ifosfamide, and methotrexate with or without bleomycin in refractory or recurrent lymphomas. Annals of Oncology. 2. 25–30. 9 indexed citations

15.

Niederle, N., et al.. (1990). Die Lebensqualität des chronisch Krebskranken. Thieme eBooks. 4 indexed citations

16.

Kloke, O., et al.. (1990). Treatment of chronic myelogenous leukemia with interferons alpha and gamma. Annals of Hematology. 61(1). 45–46. 6 indexed citations

17.

Wandl, U., Dieter May, O. Kloke, et al.. (1990). DNA-flow cytometry studies in blood and marrow cells from chronic myelogenous leukemia patients treated with interferon alpha-2b. Leukemia Research. 14(10). 905–908. 3 indexed citations

18.

Niederle, N., Wilfried Eberhardt, & H. Hirche. (1988). Prätherapeutische prognostische Faktoren beim kleinzelligen Bronchialkarzinom. Oncology Research and Treatment. 11(2). 34–40. 5 indexed citations

19.

Kloke, O., Dieter May, U. Wandl, & N. Niederle. (1988). Zur Dosierung von Interferon alpha in der Induktions und Erhaltungstherapie der Haarzellenleukämie. Oncology Research and Treatment. 11(2). 41–45. 3 indexed citations

20.

Doberauer, C., et al.. (1987). Zur Behandlung des metastasierten Karzinoids von Ileum und Caecum mit rekombinantem Interferon alpha-2b. Oncology Research and Treatment. 10(6). 340–344. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact